Gregg Stone, Columbia University Medical Center, New York American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta A superiority for the anti-clotting drug bivalirudin for t
Gregg Stone, Columbia University Medical Center, New YorkAmerican College of Cardiology Annual Scientific Session March 11-14, 2006, AtlantaA superiority for the anti-clotting drug bivalirudin for treating patients with acute coronary syndromes was detected when this was used as monotherapy, but not when this direct thrombin inhibitor was combined with glycoprotein IIb/IIIa inhibition. Thus found the ACUITY trial reported to the ACC’s Atlanta meeting by Gregg Stone of Columbia University. He told Audio Medica the bottom line finding from the study.
Related Episodes
Bivalirudin For Angioplasty: Expensive Heparin?
Tony Gershlick Tony Gershlick, University of Leicester Adnan Kastrati, Deutsches Herzzentrum, Munich Using bivalirudin instead of heparin during angioplasty wasn’t any better for preventing deat
Remove Thrombus Before Primary Angioplasty!
Felix Zijlstra Felix Zijlstra, University Medical Center Groningen, The Netherlands Thrombus aspiration before percutaneous coronary intervention for acute myocardial infarction has multiple benefits,
Heart Failure Drug Prevents Renal Damage?
Barry Massie Barry Massie, San Francisco VA Medical Center COMMENT: Aaron Kugelmass, Henry Ford Hospital, Detroit The adenosine A1-receptor antagonist rolofylline appears to prevent renal impairment a